1. Scrip

Merck & Co. CMO Eliav Barr Assures On Pipeline As Keytruda LOE Looms Large

 
• By Jessica Merrill

Chief medical officer Eliav Barr, responsible for overseeing clinical development, talked to Scrip in an interview at Merck’s headquarters about the company’s pipeline diversification.

(Shutterstock)
Key Takeaways
  • Merck & Co. chief medical officer Eliav Barr updates Scrip on the company’s portfolio diversification strategy.

Investors are acutely focused on the loss of exclusivity (LOE) of Merck & Co.’s mega-blockbuster Keytruda (pembrolizumab) in 2028, but...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Scrip

More from Therapy Areas